

LabCorp, Mount Sinai HS to develop AI-enabled pathology CoE

26 June 2019 | News

Philips IntelliSite Pathology Solution will be deployed across the Mount Sinai Health System to support greater efficiency and help improve patient care



LabCorp and the Mount Sinai Health System have announced another element in their shared goal of improving laboratory services and patient care. LabCorp, a life sciences company, and Mount Sinai, integrated healthcare delivery system in the US, will work together to establish the Mount Sinai Digital and Artificial Intelligence (AI)-Enabled Pathology Center of Excellence.

William B. Haas, senior vice president of LabCorp Diagnostics' Northeast Division said, "LabCorp and Mount Sinai continue to focus on innovations to enhance the quality and lower the costs of patient care, and we're pleased to introduce digital pathology to Mount Sinai as the next phase of our collaboration. We've taken significant steps to enhance laboratory services across the Mount Sinai system since early 2017, and we look forward to continuing to build on those successes to advance LabCorp's mission and our shared goal to improve health and improve lives."

LabCorp, which has implemented the Philips IntelliSite Pathology Solution in four of its laboratories and plans to introduce it to additional laboratories, will use its experience and expertise to lead the integration of digital pathology into clinical practice across Mount Sinai's hospitals. Initially, digital pathology will be used for interpretations of genitourinary malignancies, mainly prostate tumors, as well as cancers of the head and neck.

The next planned stage of implementation is for Mount Sinai pathologists to use the digital pathology solution to provide consultations for cases interpreted by LabCorp's Dianon Pathology specialty laboratory. This will give physicians and patients from across the U.S. access to the leading expertise of Mount Sinai specialists.

The Center of Excellence will be housed within Mount Sinai's Department of Pathology, Molecular and Cell-Based Medicine and will use the Philips IntelliSite Pathology Solution to expand digital pathology capabilities for primary diagnosis and consultations across the Mount Sinai system. The department processes more than 80 million diagnostic tests a year, making it one of the largest academic departments of its kind in the country.

Carlos Cordon-Cardo, M.D., Ph.D., chairman of the Department of Pathology, Molecular and Cell-Based Medicine at Mount Sinai Health System and professor of Pathology, Genetics and Genomic Sciences, and Oncological Sciences at the Icahn School of Medicine at Mount Sinai said, "Digital pathology gives us the unprecedented opportunity to expand our services to the community at large, and engage members of our department, considered key opinion leaders in their field, to provide expert diagnostic opinions in complex cases. This, in addition to our new predictive AI-based tests, introduces the potential for optimization of treatment efficacy, and provides the opportunity for improved clinical outcomes."

Don Scanlon, chief financial officer and chief of corporate services at Mount Sinai, added, "The Digital and AI-Enabled Pathology Center of Excellence stands to offer major operational efficiencies, extending our joint unique resources and intellectual assets more effectively to improve the lives of patients."

The Center of Excellence will include deployment of the Philips IntelliSite Pathology Solution at each of Mount Sinai's eight hospitals and select ambulatory care locations. Digital pathology will allow for real-time pathology interpretations for physicians and patients throughout the New York metropolitan area without requiring the pathologist to be on-site where the patient is receiving care.

Mount Sinai participated in Philips' digital pathology performance evaluation to obtain market clearance in the U.S., gaining valuable expertise with the research version of the digital pathology system, providing the foundation for Mount Sinai's AI diagnostic test development. Implementation of the clinical Philips IntelliSite Pathology Solution is underway and Mount Sinai expects to begin its use in the next several months.

Marlon Thompson, general manager, Philips Digital & Computational Pathology said, "Digital pathology provides a unique opportunity to innovate laboratory pathology services and support pathologists in their daily practice. The Philips IntelliSite Pathology Solution is designed for scale and clinical pathologists' workflows, enabling immediate access to consultations and helping leading institutions such as Mount Sinai and LabCorp to collaborate and deliver high-quality care."

The Philips IntelliSite Pathology Solution is the first, and currently the only, digital pathology solution marketed for primary diagnostic use in the U.S. It aids pathologists in the review and interpretation of digital images of surgical pathology slides through an automated digital pathology image creation, viewing and management system.

With an ultra-fast scanner, image management system, high-resolution display and advanced software tools, the system aims to support more efficient workflows, faster turnaround times, and enhanced collaboration between pathologists to enhance diagnostic decision-making.

LabCorp plans to expand digital pathology to more of its laboratories in the coming year and is working with key partners such as Mount Sinai to help support their transition to digital pathology and AI in the future.